
The phase 2b trial evaluated BCG revaccination for preventing sustained Mycobacterium tuberculosis infection in adolescents. Despite initial promise in a prior study, BCG revaccination showed no efficacy in preventing sustained QFT test conversion after 30 months of follow-up. Although adverse events were more frequent in the BCG group, vaccine-induced immune responses were observed, but the overall protection against tuberculosis was not achieved.
Like
Save
Share